Do pharmaceutical marketing activities raise prices? Evidence from five major therapeutic classes

Journal of Public Policy and Marketing

Volumn 28, Issue 2, 2009, Pages 146-161

  Capella, Michael L ^a   Taylor, Charles R ^a   Campbell, Randall C ^b   Longwell, Lance S ^c  

^a VILLANOVA UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Advertising effects; Direct to consumer advertising; Pharmaceutical marketing; Pricing

Indexed keywords

EID: 73949103209     PISSN: 07439156     EISSN: 15477207     Source Type: Journal    
DOI: 10.1509/jppm.28.2.146     Document Type: Article

References (62)

1. Aitken, Murray, Ernst R. Berndt, and David M. Cutler (2009), "Prescription Drug Spending Trends in the United States: Looking Beyond the Turning Point," Health Affairs, 28 (1), 151-60.
2. Anand, Geeta (2007), "From Wall Street, a Warning About Cancer-Drug Prices," The Wall Street Journal, (March 15), Al.
3. Appleby, Julie (2008), "Drug Costs Rise as Economy Slides," USA Today, (April 3), (accessed July 15, 2009), [available at http://www.usatoday. com/money/industries/health/drugs/2008-04-02-drugs-N.htm].
4. Auton, Frank (2004), "The Advertising of Pharmaceuticals Direct to Consumers: A Critical Review of the Literature and Debate," International Journal of Advertising, 23 (1), 5-52.
5. Azoulay, Pierre (2002), "Do Pharmaceutical Sales Respond to Scientific Evidence," Journal of Economics and Management Strategy, 11 (4), 551-94.
6. Bain, Joe S. (1956), Barriers to New Competition: Their Character and Consequences in Manufacturing Industries. Cambridge, MA: Harvard University Press.
7. Bakos, J. Yannis (1997), "Reducing Buyer Search Costs: Implications for Electronic Marketplaces," Management Science, 43 (2), 1676-92.
8. Berndt, Ernst R. (2002), "Pharmaceuticals in U.S. Health Care: Determinants of Quality and Price," Journal of Economic Perspectives, 16 (4), 45-66.
9. -(2007), "The United States Experience with Direct-to- Consumer Advertising of Prescription Drugs: What Have We Learned?" in Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, chap. 9, Frank A. Sloan and Chee-Ruey Hsieh, eds. Cambridge, UK: Cambridge University Press, 174-95.
10. -, Linda Bui, David Reiley, and Glen Urban (1995), "Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market," American Economic Review, 85 (2), 100-105.
11. Bhattacharya, Jayanta and William B. Vogt (2003), "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics, 46 (October), 599-626.
12. Bixler, Edward O., Anthony Kales, Constantine R. Soldatos, Joyce D. Kales, and S. Healey (1979), "Prevalence of Sleep Disorders in the Los Angeles Metropolitan Area," American Journal of Psychiatry, 136 (10), 1257-62.
13. Calfee, John E. (2002), "Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs," Journal of Public Policy & Marketing, 21 (Fall), 174-93.
14. -(2007), "An Assessment of Direct-to-Consumer Advertising of Prescription Drugs," Clinical Pharmacology and Therapeutics, 82 (4), 357-60.
15. Clarke, Darral G. (1976), "Econometric Measurement of the Duration of Advertising Effect on Sales," Journal of Marketing Research, 13 (November), 345-57.
16. Comanor, William S. and Thomas A. Wilson (1974), "Advertising, Market Structure and Performance," Review of Economics and Statistics, 49 (November), 423-40.
17. Donohue, Julie M. and Ernst R. Berndt (2004), "Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants," Journal of Public Policy & Marketing, 23 (Fall), 115-27.
18. Express Scripts Inc. (2006), "DrugDigest.com," (May), (accessed April 3, 2007), [available at http://www.drugdigest.org/DD/HC/HCIntro/0,4043, 930,00.html]
19. Farris, Paul W. and Mark S. Albion (1980), "The Impact of Advertising on the Price of Consumer Products," Journal of Marketing, 44 (July), 17-35.
20. Ferguson, James M. (1982), "Comments on 'The Impact of Advertising on the Price of Consumer Products,'" Journal of Marketing, 46 (Winter), 102-105.
21. Ford, Daniel E. and Douglas B. Kamerow (1989), "Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders. An Opportunity for Prevention," Journal of the American Medical Association, 262 (11), 1479-84.
22. Frank, Richard G. (2001), "Prescription Drug Prices: Why Do Some Pay More Than Others Do?" Health Affairs, 20 (2), 115-28.
23. GlaxoSmithKline (2007), "Welcome to Depression.com," (accessed April 3, 2009), [available at http://www.depression. com/].
24. Gonul, Fusun, Franklin Carter, Elina Petrova, and Kannan Srinivasan (2001), "Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," Journal of Marketing, 65 (July), 79-90.
25. Hartman, Micah, Anne Martin, Patricia McDonnell, Aaron Catlin, and the National Health Expenditure Accounts Team (2009), "National Health Spending in 2007: Slower Drug Spending Contributes to Lowest Rate of Overall Growth Since 1998," Health Affairs, 28 (1), 246-61.
26. Hellerstein, Judith K. (1994), "The Demand for Post-Patent Prescription Pharmaceuticals," NBER Working Paper No. W4981.
27. Hoek, Janet and Phillip Gendall (2002), "Direct-to-Consumer Advertising Down Under: An Alternative Perspective and Regulatory Framework," Journal of Public Policy & Marketing, 21 (Fall), 202-212.
28. -,-, and John Calfee (2004), "Direct to Consumer Advertising of Prescription Medicines in the United States and New Zealand: An Analysis of Regulatory Approaches and Consumer Responses," International Journal of Advertising, 23 (2), 197-227.
29. Huh, Jisu and Lee B. Becker (2005), "Direct-to-Consumer Prescription Drug Advertising: Understanding Its Consequences," International Journal of Advertising, 24 (4), 441-66.
30. Iizuka, Toshiaki and Ginger Z. Jin (2005), "The Effect of Prescription Drug Advertising on Doctor Visits," Journal of Economics and Management Strategy, 14 (3), 701-717.
31. Kaiser Family Foundation (2008), "USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies," (March 4), (accessed July 15, 2009), [available at http://www. kff.org/kaiserpolls/pomr030408pkg.cfm].
32. Kaldor, Nicholas (1950), "The Economic Aspects of Advertising," Review of Economic Studies, 18 (1), 1-27.
33. Kanetkar, Vinay, Charles B. Weinberg, and Doyle L. Weiss (1992), "Price Sensitivity and Television Advertising Exposures: Some Empirical Findings," Marketing Science, 11 (Fall), 359-71.
34. Kaul, Anil and Dick R. Wittink (1995), "Empirical Generalizations About the Impact of Advertising on Price Sensitivity and Price," Marketing Science, 14 (3), 151-60.
35. Kravitz, Richard L, Ronald M. Epstein, Mitchell D. Feldman, Carol E. Franz, Rahman Azari, Michael S. Wilkes, et al. (2005), "Influence of Patients' Requests for Direct-to-Consumer Advertised Antidepressants," Journal of the American Medical Association, 293 (16), 1995-2002.
36. Lynch, John G., Jr., and Dan Ariely (2000), "Wine Online: Search Costs Affect Competition on Price, Quality, and Distribution," Marketing Science, 19 (1), 83-103.
37. Macias, Wendy and Liza S. Lewis (2005), "How Well Do Direct-to-Consumer (DTC) Prescription Drug Web Sites Meet FDA Guidelines and Public Policy Concerns," Health Marketing Quarterly, 22(4), 45-71.
38. Manchanda, Puneet and Elizabeth Honka (2005), "The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review," Yale Journal of Health Policy Law Ethics, 5 (2), 785-822.
39. Manning, Richard L. and Alison Keith (2001), "The Economics of Direct-to-Consumer Advertising of Prescription Drugs," Economic Realities in Health Care, 2(1), 3-9.
40. Masia, Neal (2003), "Economic Impact of DTC Advertising," paper presented at the U.S. Food and Drug Administration public hearing on Direct-to-Consumer Promotion, (September 23).
41. McAuliffe, Robert E. (1987), Advertising, Competition, and, Public Policy: Theories and New Evidence. Lexington, MA: DC Heath and Company.
42. Mitra, Anusree and John G. Lynch (1995), "Toward a Reconciliation of Market Power and Information Theories of Advertising Effects on Price Elasticity," Journal of Consumer Research, 21 (March), 644-59.
43. Narayanan, Sridhar, Ramarao Desiraju, and Pradeep K. Chintagunta (2004), "Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions," Journal of Marketing, 68 (October), 90-105.
44. Nelson, Paul (1974), "Advertising as Information," Journal of Political Economy, 24 (July-August), 729-45.
45. Neslin, Scott A. (2001), "ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study," (May 22), (accessed July 15, 2009), [available at http://www.rxpromoroi.org/rapp/media/slides-speakernotes.pdf].
46. Ornstein, Stanley I. (1977), Industrial Concentration and Advertising Intensity. Washington, DC: American Enterprise Institute.
47. Palda, Kristian S. (1964), The Measurement of Cumulative Advertising Effects. Englewood Cliffs, NJ: Prentice Hall.
48. Palleschi, Giovanni and Andrea Tubaro (2005), "Overactive Bladder: Epidemiology and Social Impact," Current Opinion in Obstetrics & Gynecology, 17 (5), 507-511.
49. Rizzo, John A. (1999), "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs," Journal of Law and Economics, 42 (1), 89-116.
50. Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Arnold E. Epstein, and Richard G. Frank (2003), "Demand Effects of Recent Changes in Prescription Drug Promotion," Frontiers in Health Policy Research, 6, 1-26.
51. Rovner, Eric S. and Alan J. Wein (2002), "Definition and Epidemiology of Overactive Bladder," Urology, 60 (Supplement 5A), 7-12.
52. Singh, Tangua and Donna Smith (2005), "Direct-to-Consumer Prescription Advertising: A Study of Consumer Attitudes and Behavioral Intentions," Journal of Consumer Marketing, 22 (7), 369-78.
53. Stewart, W.F., J.B. Van Rooyen, G.W. Cundiff, P. Abrams, A. Herzog, R. Corey, et al. (2003), "Prevalence and Burden of Overactive Bladder in the United States," World Journal of Urology, 20 (6), 327-36. (Pubitemid 44175300)
54. Stigler, George J. (1961), "The Economics of Information," Journal of the Political Economy, 69 (June), 231-35.
55. Taylor, Charles R., Michael L. Capella, and John C. Kozup (2007), "Does DTC Advertising Provide Information or Create Market Power? Evidence from the U.S. and New Zealand," in Advances in International Marketing, Vol. 18, Charles R. Taylor and Doo-Hee Lee, eds. Bingley, UK: Emerald, 9-30.
56. -, Shaoming Zou, and Aysegul Ozsomer (1995), "Advertising and Its Effect on Industrial Concentration: A Contingency Perspective," Journal of Current Issues and Research in Advertising, 18 (Spring), 35-44.
57. Teinowitz, Ira (2006), "Democrats Set Sights on Drug Ads and Media Ownership," Advertising Age, (November 8), (accessed July 15, 2009), [available at http://adage.com/].
58. Telser, Lester (1964), "Advertising and Competition," Journal of Political Economy, 72 (December), 537-62.
59. Toop, Les, Dee Richards, Tony Dowell, Murray Tilyard, Tony Fraser, and Bruce Arroll (2003), "Direct to Consumer Advertising of Prescription Drugs in New Zealand: For Health or for Profit?" report to the Minister of Health, New Zealand Departments of General Practice, (November).
60. Weissman, Joel S., David Blumenthal, Alvin J. Silk, and Kinga Zapert (2003), "Consumers' Reports on the Health Effects of Direct-to-Consumer Drug Advertising," Health Affairs, (January-June), 82-95.
61. Wittink, Dick R. (2002), "Analysis of ROI for Pharmaceutical Promotions (ARPP)," (September 18), (accessed July 15, 2009), [available at http://www.rxpromoroi.org/arpp/media/arpp-handout-0927.pdf].
62. Wosinka, Marta (2002), "Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products," working paper, Harvard Business School, Harvard University.